On a supply shelf, a stabilized saliva kit and a dry buccal swab look like interchangeable ways to collect cheek-derived DNA. At the bench, they are not. The stabilization chemistry that defines an Oragene-style kit changes the yield, the stability, and the failure rate in ways that decide whether a panel runs clean.
Yield is the first divergence. A stabilized saliva kit captures a large, cell-rich volume and locks it in a preservative buffer, routinely out-yielding a dry swab that collects a thin smear of epithelial cells. For assays with a real input threshold, that margin is the difference between a confident extraction and a borderline one.
Stability is the second. The saliva buffer holds DNA intact at room temperature for weeks, while a dry swab is more exposed to degradation in transit. The third and most operational difference is the failed-collection rate: swabs fail more often in real-world, patient-collected use, and every failure means a re-collection, a delay, and an anxious patient.
None of this makes the swab obsolete — it remains the right tool for pediatric or frail patients and observed collections. But for default patient-collected germline work, stabilized saliva wins on the numbers. If you are specifying kits for a program, start with a full buyer’s guide to DNA saliva collection kits and validate the swab only for the use cases that genuinely need it.